nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Sunitinib—pancreatic cancer	0.688	1	CrCtD
Metoclopramide—Procainamide—Sunitinib—pancreatic cancer	0.251	1	CrCrCtD
Metoclopramide—HTR3A—enteric nervous system—pancreatic cancer	0.00372	0.852	CbGeAlD
Metoclopramide—Sunitinib—STK11—pancreatic cancer	0.000935	0.735	CrCbGaD
Metoclopramide—HTR3A—islet of Langerhans—pancreatic cancer	0.000355	0.0814	CbGeAlD
Metoclopramide—Sunitinib—KDR—pancreatic cancer	0.000337	0.265	CrCbGaD
Metoclopramide—HTR3A—digestive system—pancreatic cancer	0.000213	0.0489	CbGeAlD
Metoclopramide—Neutropenia—Sunitinib—pancreatic cancer	0.000173	0.00607	CcSEcCtD
Metoclopramide—Respiratory failure—Docetaxel—pancreatic cancer	0.000171	0.006	CcSEcCtD
Metoclopramide—Cardiac arrest—Irinotecan—pancreatic cancer	0.000168	0.00588	CcSEcCtD
Metoclopramide—Visual impairment—Tamoxifen—pancreatic cancer	0.000167	0.00584	CcSEcCtD
Metoclopramide—Depression—Sunitinib—pancreatic cancer	0.000165	0.00577	CcSEcCtD
Metoclopramide—Cardiac arrest—Fluorouracil—pancreatic cancer	0.000161	0.00563	CcSEcCtD
Metoclopramide—Flushing—Tamoxifen—pancreatic cancer	0.00016	0.00563	CcSEcCtD
Metoclopramide—Fluid retention—Docetaxel—pancreatic cancer	0.000159	0.00559	CcSEcCtD
Metoclopramide—Bradycardia—Sunitinib—pancreatic cancer	0.000151	0.00529	CcSEcCtD
Metoclopramide—Bronchospasm—Gemcitabine—pancreatic cancer	0.000146	0.00512	CcSEcCtD
Metoclopramide—Muscle spasms—Tamoxifen—pancreatic cancer	0.000145	0.00507	CcSEcCtD
Metoclopramide—Neutropenia—Irinotecan—pancreatic cancer	0.000143	0.005	CcSEcCtD
Metoclopramide—Neutropenia—Gemcitabine—pancreatic cancer	0.000139	0.00487	CcSEcCtD
Metoclopramide—Angioedema—Tamoxifen—pancreatic cancer	0.000138	0.00482	CcSEcCtD
Metoclopramide—Flushing—Sunitinib—pancreatic cancer	0.000137	0.00482	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—pancreatic cancer	0.000136	0.00476	CcSEcCtD
Metoclopramide—Leukopenia—Tamoxifen—pancreatic cancer	0.000135	0.00472	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Docetaxel—pancreatic cancer	0.000134	0.00471	CcSEcCtD
Metoclopramide—Jaundice—Irinotecan—pancreatic cancer	0.000132	0.00464	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—pancreatic cancer	0.000132	0.00462	CcSEcCtD
Metoclopramide—Hypertension—Tamoxifen—pancreatic cancer	0.00013	0.00456	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—pancreatic cancer	0.000129	0.00452	CcSEcCtD
Metoclopramide—Visual disturbance—Docetaxel—pancreatic cancer	0.000129	0.00451	CcSEcCtD
Metoclopramide—Atrial fibrillation—Docetaxel—pancreatic cancer	0.000129	0.00451	CcSEcCtD
Metoclopramide—Renal impairment—Docetaxel—pancreatic cancer	0.000128	0.00449	CcSEcCtD
Metoclopramide—Anxiety—Tamoxifen—pancreatic cancer	0.000128	0.00448	CcSEcCtD
Metoclopramide—Anxiety—Erlotinib—pancreatic cancer	0.000126	0.00443	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—pancreatic cancer	0.000125	0.0044	CcSEcCtD
Metoclopramide—Bradycardia—Irinotecan—pancreatic cancer	0.000124	0.00435	CcSEcCtD
Metoclopramide—Muscle spasms—Sunitinib—pancreatic cancer	0.000124	0.00435	CcSEcCtD
Metoclopramide—Agranulocytosis—Gemcitabine—pancreatic cancer	0.000124	0.00433	CcSEcCtD
Metoclopramide—Oedema—Tamoxifen—pancreatic cancer	0.000123	0.00431	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—pancreatic cancer	0.000122	0.00427	CcSEcCtD
Metoclopramide—Oedema—Erlotinib—pancreatic cancer	0.000122	0.00426	CcSEcCtD
Metoclopramide—Agranulocytosis—Fluorouracil—pancreatic cancer	0.000121	0.00426	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—pancreatic cancer	0.000121	0.00423	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—pancreatic cancer	0.000119	0.00418	CcSEcCtD
Metoclopramide—Angioedema—Sunitinib—pancreatic cancer	0.000118	0.00413	CcSEcCtD
Metoclopramide—Visual impairment—Irinotecan—pancreatic cancer	0.000118	0.00412	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—pancreatic cancer	0.000117	0.00409	CcSEcCtD
Metoclopramide—Leukopenia—Sunitinib—pancreatic cancer	0.000115	0.00405	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—pancreatic cancer	0.000113	0.00397	CcSEcCtD
Metoclopramide—Flushing—Irinotecan—pancreatic cancer	0.000113	0.00397	CcSEcCtD
Metoclopramide—Convulsion—Sunitinib—pancreatic cancer	0.000112	0.00392	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—pancreatic cancer	0.000112	0.00391	CcSEcCtD
Metoclopramide—Hypertension—Sunitinib—pancreatic cancer	0.000111	0.0039	CcSEcCtD
Metoclopramide—Insomnia—Tamoxifen—pancreatic cancer	0.000111	0.0039	CcSEcCtD
Metoclopramide—Insomnia—Erlotinib—pancreatic cancer	0.00011	0.00385	CcSEcCtD
Metoclopramide—Dyspnoea—Tamoxifen—pancreatic cancer	0.00011	0.00384	CcSEcCtD
Metoclopramide—Dyspnoea—Erlotinib—pancreatic cancer	0.000108	0.0038	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—pancreatic cancer	0.000108	0.00379	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—pancreatic cancer	0.000108	0.00377	CcSEcCtD
Metoclopramide—Fatigue—Tamoxifen—pancreatic cancer	0.000106	0.00371	CcSEcCtD
Metoclopramide—Oedema—Sunitinib—pancreatic cancer	0.000105	0.00369	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—pancreatic cancer	0.000105	0.00368	CcSEcCtD
Metoclopramide—Fatigue—Erlotinib—pancreatic cancer	0.000105	0.00367	CcSEcCtD
Metoclopramide—Bronchospasm—Docetaxel—pancreatic cancer	0.000104	0.00363	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000103	0.00361	CcSEcCtD
Metoclopramide—Muscle spasms—Irinotecan—pancreatic cancer	0.000102	0.00358	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—pancreatic cancer	9.95e-05	0.00349	CcSEcCtD
Metoclopramide—Neutropenia—Docetaxel—pancreatic cancer	9.85e-05	0.00345	CcSEcCtD
Metoclopramide—Urticaria—Tamoxifen—pancreatic cancer	9.76e-05	0.00342	CcSEcCtD
Metoclopramide—Body temperature increased—Erlotinib—pancreatic cancer	9.61e-05	0.00337	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—pancreatic cancer	9.53e-05	0.00334	CcSEcCtD
Metoclopramide—Insomnia—Sunitinib—pancreatic cancer	9.52e-05	0.00334	CcSEcCtD
Metoclopramide—Leukopenia—Irinotecan—pancreatic cancer	9.51e-05	0.00333	CcSEcCtD
Metoclopramide—Dyspnoea—Sunitinib—pancreatic cancer	9.38e-05	0.00329	CcSEcCtD
Metoclopramide—Leukopenia—Gemcitabine—pancreatic cancer	9.26e-05	0.00325	CcSEcCtD
Metoclopramide—Hypertension—Irinotecan—pancreatic cancer	9.17e-05	0.00321	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—pancreatic cancer	9.16e-05	0.00321	CcSEcCtD
Metoclopramide—Leukopenia—Fluorouracil—pancreatic cancer	9.1e-05	0.00319	CcSEcCtD
Metoclopramide—Fatigue—Sunitinib—pancreatic cancer	9.07e-05	0.00318	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—pancreatic cancer	9.07e-05	0.00318	CcSEcCtD
Metoclopramide—Hypersensitivity—Tamoxifen—pancreatic cancer	9.05e-05	0.00317	CcSEcCtD
Metoclopramide—Hypertension—Gemcitabine—pancreatic cancer	8.93e-05	0.00313	CcSEcCtD
Metoclopramide—Asthenia—Tamoxifen—pancreatic cancer	8.81e-05	0.00309	CcSEcCtD
Metoclopramide—Convulsion—Fluorouracil—pancreatic cancer	8.81e-05	0.00309	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—pancreatic cancer	8.77e-05	0.00307	CcSEcCtD
Metoclopramide—Confusional state—Irinotecan—pancreatic cancer	8.74e-05	0.00306	CcSEcCtD
Metoclopramide—Asthenia—Erlotinib—pancreatic cancer	8.72e-05	0.00306	CcSEcCtD
Metoclopramide—Oedema—Irinotecan—pancreatic cancer	8.67e-05	0.00304	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—pancreatic cancer	8.64e-05	0.00303	CcSEcCtD
Metoclopramide—Oedema—Gemcitabine—pancreatic cancer	8.44e-05	0.00296	CcSEcCtD
Metoclopramide—Diarrhoea—Tamoxifen—pancreatic cancer	8.41e-05	0.00295	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—pancreatic cancer	8.39e-05	0.00294	CcSEcCtD
Metoclopramide—Confusional state—Fluorouracil—pancreatic cancer	8.37e-05	0.00293	CcSEcCtD
Metoclopramide—Body temperature increased—Sunitinib—pancreatic cancer	8.32e-05	0.00292	CcSEcCtD
Metoclopramide—Diarrhoea—Erlotinib—pancreatic cancer	8.32e-05	0.00292	CcSEcCtD
Metoclopramide—Oedema—Fluorouracil—pancreatic cancer	8.3e-05	0.00291	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—pancreatic cancer	8.13e-05	0.00285	CcSEcCtD
Metoclopramide—Dizziness—Tamoxifen—pancreatic cancer	8.12e-05	0.00285	CcSEcCtD
Metoclopramide—Tachycardia—Fluorouracil—pancreatic cancer	8.1e-05	0.00284	CcSEcCtD
Metoclopramide—Hypotension—Irinotecan—pancreatic cancer	8.1e-05	0.00284	CcSEcCtD
Metoclopramide—Dizziness—Erlotinib—pancreatic cancer	8.04e-05	0.00282	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—pancreatic cancer	7.99e-05	0.0028	CcSEcCtD
Metoclopramide—Hypotension—Gemcitabine—pancreatic cancer	7.89e-05	0.00277	CcSEcCtD
Metoclopramide—Insomnia—Irinotecan—pancreatic cancer	7.84e-05	0.00275	CcSEcCtD
Metoclopramide—CYP2D6—digestive system—pancreatic cancer	7.84e-05	0.018	CbGeAlD
Metoclopramide—Flushing—Docetaxel—pancreatic cancer	7.83e-05	0.00274	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—pancreatic cancer	7.82e-05	0.00274	CcSEcCtD
Metoclopramide—Hypotension—Fluorouracil—pancreatic cancer	7.76e-05	0.00272	CcSEcCtD
Metoclopramide—Hypersensitivity—Sunitinib—pancreatic cancer	7.75e-05	0.00272	CcSEcCtD
Metoclopramide—Rash—Tamoxifen—pancreatic cancer	7.75e-05	0.00272	CcSEcCtD
Metoclopramide—Dermatitis—Tamoxifen—pancreatic cancer	7.74e-05	0.00271	CcSEcCtD
Metoclopramide—Dyspnoea—Irinotecan—pancreatic cancer	7.73e-05	0.00271	CcSEcCtD
Metoclopramide—Somnolence—Irinotecan—pancreatic cancer	7.71e-05	0.0027	CcSEcCtD
Metoclopramide—Headache—Tamoxifen—pancreatic cancer	7.7e-05	0.0027	CcSEcCtD
Metoclopramide—Rash—Erlotinib—pancreatic cancer	7.66e-05	0.00269	CcSEcCtD
Metoclopramide—Dermatitis—Erlotinib—pancreatic cancer	7.66e-05	0.00268	CcSEcCtD
Metoclopramide—Insomnia—Gemcitabine—pancreatic cancer	7.64e-05	0.00268	CcSEcCtD
Metoclopramide—Headache—Erlotinib—pancreatic cancer	7.61e-05	0.00267	CcSEcCtD
Metoclopramide—Asthenia—Sunitinib—pancreatic cancer	7.55e-05	0.00265	CcSEcCtD
Metoclopramide—Dyspnoea—Gemcitabine—pancreatic cancer	7.53e-05	0.00264	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—pancreatic cancer	7.51e-05	0.00263	CcSEcCtD
Metoclopramide—Somnolence—Gemcitabine—pancreatic cancer	7.51e-05	0.00263	CcSEcCtD
Metoclopramide—Fatigue—Irinotecan—pancreatic cancer	7.47e-05	0.00262	CcSEcCtD
Metoclopramide—Dyspnoea—Fluorouracil—pancreatic cancer	7.4e-05	0.00259	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—pancreatic cancer	7.38e-05	0.00259	CcSEcCtD
Metoclopramide—Nausea—Tamoxifen—pancreatic cancer	7.3e-05	0.00256	CcSEcCtD
Metoclopramide—Fatigue—Gemcitabine—pancreatic cancer	7.28e-05	0.00255	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—pancreatic cancer	7.23e-05	0.00254	CcSEcCtD
Metoclopramide—Nausea—Erlotinib—pancreatic cancer	7.22e-05	0.00253	CcSEcCtD
Metoclopramide—Diarrhoea—Sunitinib—pancreatic cancer	7.2e-05	0.00252	CcSEcCtD
Metoclopramide—Feeling abnormal—Irinotecan—pancreatic cancer	7.14e-05	0.0025	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—pancreatic cancer	7.11e-05	0.00249	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—pancreatic cancer	7.06e-05	0.00247	CcSEcCtD
Metoclopramide—Dizziness—Sunitinib—pancreatic cancer	6.96e-05	0.00244	CcSEcCtD
Metoclopramide—Feeling abnormal—Gemcitabine—pancreatic cancer	6.96e-05	0.00244	CcSEcCtD
Metoclopramide—Body temperature increased—Irinotecan—pancreatic cancer	6.85e-05	0.0024	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—pancreatic cancer	6.84e-05	0.0024	CcSEcCtD
Metoclopramide—Body temperature increased—Gemcitabine—pancreatic cancer	6.67e-05	0.00234	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—pancreatic cancer	6.65e-05	0.00233	CcSEcCtD
Metoclopramide—Rash—Sunitinib—pancreatic cancer	6.63e-05	0.00233	CcSEcCtD
Metoclopramide—Dermatitis—Sunitinib—pancreatic cancer	6.63e-05	0.00232	CcSEcCtD
Metoclopramide—Urticaria—Fluorouracil—pancreatic cancer	6.59e-05	0.00231	CcSEcCtD
Metoclopramide—Headache—Sunitinib—pancreatic cancer	6.59e-05	0.00231	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—pancreatic cancer	6.58e-05	0.00231	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—pancreatic cancer	6.57e-05	0.0023	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—pancreatic cancer	6.57e-05	0.0023	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—pancreatic cancer	6.56e-05	0.0023	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—pancreatic cancer	6.49e-05	0.00227	CcSEcCtD
Metoclopramide—Hypersensitivity—Irinotecan—pancreatic cancer	6.39e-05	0.00224	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—pancreatic cancer	6.36e-05	0.00223	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—pancreatic cancer	6.34e-05	0.00222	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—pancreatic cancer	6.34e-05	0.00222	CcSEcCtD
Metoclopramide—Nausea—Sunitinib—pancreatic cancer	6.25e-05	0.00219	CcSEcCtD
Metoclopramide—Asthenia—Irinotecan—pancreatic cancer	6.22e-05	0.00218	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—pancreatic cancer	6.18e-05	0.00217	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—pancreatic cancer	6.15e-05	0.00216	CcSEcCtD
Metoclopramide—Hypersensitivity—Fluorouracil—pancreatic cancer	6.12e-05	0.00214	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—pancreatic cancer	6.07e-05	0.00213	CcSEcCtD
Metoclopramide—Asthenia—Gemcitabine—pancreatic cancer	6.06e-05	0.00212	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—pancreatic cancer	6.04e-05	0.00212	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—pancreatic cancer	5.99e-05	0.0021	CcSEcCtD
Metoclopramide—Diarrhoea—Irinotecan—pancreatic cancer	5.93e-05	0.00208	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—pancreatic cancer	5.91e-05	0.00207	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—pancreatic cancer	5.86e-05	0.00206	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—pancreatic cancer	5.85e-05	0.00205	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—pancreatic cancer	5.79e-05	0.00203	CcSEcCtD
Metoclopramide—Diarrhoea—Gemcitabine—pancreatic cancer	5.78e-05	0.00203	CcSEcCtD
Metoclopramide—Dizziness—Irinotecan—pancreatic cancer	5.73e-05	0.00201	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—pancreatic cancer	5.71e-05	0.002	CcSEcCtD
Metoclopramide—Diarrhoea—Fluorouracil—pancreatic cancer	5.68e-05	0.00199	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—pancreatic cancer	5.6e-05	0.00196	CcSEcCtD
Metoclopramide—Dizziness—Fluorouracil—pancreatic cancer	5.49e-05	0.00192	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—pancreatic cancer	5.48e-05	0.00192	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—pancreatic cancer	5.47e-05	0.00192	CcSEcCtD
Metoclopramide—Rash—Irinotecan—pancreatic cancer	5.47e-05	0.00192	CcSEcCtD
Metoclopramide—Dermatitis—Irinotecan—pancreatic cancer	5.46e-05	0.00191	CcSEcCtD
Metoclopramide—Headache—Irinotecan—pancreatic cancer	5.43e-05	0.0019	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—pancreatic cancer	5.42e-05	0.0019	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—pancreatic cancer	5.36e-05	0.00188	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—pancreatic cancer	5.34e-05	0.00187	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—pancreatic cancer	5.33e-05	0.00187	CcSEcCtD
Metoclopramide—Rash—Gemcitabine—pancreatic cancer	5.32e-05	0.00187	CcSEcCtD
Metoclopramide—Dermatitis—Gemcitabine—pancreatic cancer	5.32e-05	0.00186	CcSEcCtD
Metoclopramide—Headache—Gemcitabine—pancreatic cancer	5.29e-05	0.00185	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—pancreatic cancer	5.28e-05	0.00185	CcSEcCtD
Metoclopramide—Rash—Fluorouracil—pancreatic cancer	5.23e-05	0.00184	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—pancreatic cancer	5.23e-05	0.00183	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—pancreatic cancer	5.2e-05	0.00182	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—pancreatic cancer	5.17e-05	0.00181	CcSEcCtD
Metoclopramide—Nausea—Irinotecan—pancreatic cancer	5.15e-05	0.00181	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—pancreatic cancer	5.07e-05	0.00178	CcSEcCtD
Metoclopramide—Nausea—Gemcitabine—pancreatic cancer	5.02e-05	0.00176	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—pancreatic cancer	4.94e-05	0.00173	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—pancreatic cancer	4.93e-05	0.00173	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—pancreatic cancer	4.88e-05	0.00171	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—pancreatic cancer	4.81e-05	0.00169	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—pancreatic cancer	4.76e-05	0.00167	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—pancreatic cancer	4.74e-05	0.00166	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—pancreatic cancer	4.55e-05	0.0016	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—pancreatic cancer	4.45e-05	0.00156	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—pancreatic cancer	4.43e-05	0.00155	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—pancreatic cancer	4.41e-05	0.00155	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—pancreatic cancer	4.41e-05	0.00154	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—pancreatic cancer	4.38e-05	0.00153	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—pancreatic cancer	4.3e-05	0.00151	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—pancreatic cancer	4.29e-05	0.0015	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—pancreatic cancer	4.28e-05	0.0015	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—pancreatic cancer	4.21e-05	0.00148	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—pancreatic cancer	4.2e-05	0.00147	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—pancreatic cancer	4.1e-05	0.00144	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—pancreatic cancer	4.1e-05	0.00144	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—pancreatic cancer	4.07e-05	0.00143	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—pancreatic cancer	4.05e-05	0.00142	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—pancreatic cancer	4.04e-05	0.00142	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—pancreatic cancer	3.97e-05	0.00139	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—pancreatic cancer	3.96e-05	0.00139	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—pancreatic cancer	3.96e-05	0.00139	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—pancreatic cancer	3.94e-05	0.00138	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—pancreatic cancer	3.89e-05	0.00136	CcSEcCtD
Metoclopramide—Rash—Docetaxel—pancreatic cancer	3.78e-05	0.00132	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—pancreatic cancer	3.78e-05	0.00132	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—pancreatic cancer	3.77e-05	0.00132	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—pancreatic cancer	3.77e-05	0.00132	CcSEcCtD
Metoclopramide—Headache—Docetaxel—pancreatic cancer	3.75e-05	0.00132	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—pancreatic cancer	3.74e-05	0.00131	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—pancreatic cancer	3.66e-05	0.00128	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—pancreatic cancer	3.65e-05	0.00128	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—pancreatic cancer	3.6e-05	0.00126	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—pancreatic cancer	3.59e-05	0.00126	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—pancreatic cancer	3.56e-05	0.00125	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—pancreatic cancer	3.49e-05	0.00123	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—pancreatic cancer	3.48e-05	0.00122	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—pancreatic cancer	3.38e-05	0.00119	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—pancreatic cancer	3.33e-05	0.00117	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—pancreatic cancer	3.33e-05	0.00117	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—pancreatic cancer	3.32e-05	0.00117	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—pancreatic cancer	3.22e-05	0.00113	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—pancreatic cancer	3.21e-05	0.00113	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—pancreatic cancer	3.19e-05	0.00112	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—pancreatic cancer	3.08e-05	0.00108	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—pancreatic cancer	2.98e-05	0.00104	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—pancreatic cancer	2.97e-05	0.00104	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—pancreatic cancer	2.96e-05	0.00104	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—pancreatic cancer	2.9e-05	0.00102	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—pancreatic cancer	2.77e-05	0.00097	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—pancreatic cancer	2.76e-05	0.000966	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—pancreatic cancer	2.68e-05	0.000941	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—pancreatic cancer	2.67e-05	0.000937	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—pancreatic cancer	2.56e-05	0.000897	CcSEcCtD
Metoclopramide—Rash—Epirubicin—pancreatic cancer	2.55e-05	0.000893	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—pancreatic cancer	2.55e-05	0.000893	CcSEcCtD
Metoclopramide—Headache—Epirubicin—pancreatic cancer	2.53e-05	0.000888	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—pancreatic cancer	2.47e-05	0.000867	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—pancreatic cancer	2.4e-05	0.000842	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—pancreatic cancer	2.36e-05	0.000827	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—pancreatic cancer	2.36e-05	0.000826	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—pancreatic cancer	2.34e-05	0.000821	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—pancreatic cancer	2.22e-05	0.000779	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—PPARG—pancreatic cancer	8.37e-06	0.000313	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL8—pancreatic cancer	8.28e-06	0.00031	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—pancreatic cancer	8.23e-06	0.000308	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SCT—pancreatic cancer	8.22e-06	0.000308	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HEY1—pancreatic cancer	8.22e-06	0.000308	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CG—pancreatic cancer	8.11e-06	0.000304	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HEY1—pancreatic cancer	8.04e-06	0.000301	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SCT—pancreatic cancer	8.04e-06	0.000301	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—pancreatic cancer	8e-06	0.0003	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CASP3—pancreatic cancer	7.93e-06	0.000297	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCK—pancreatic cancer	7.84e-06	0.000294	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—pancreatic cancer	7.83e-06	0.000293	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	7.78e-06	0.000291	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SST—pancreatic cancer	7.77e-06	0.000291	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—pancreatic cancer	7.72e-06	0.000289	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CB—pancreatic cancer	7.71e-06	0.000289	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCK—pancreatic cancer	7.67e-06	0.000287	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.66e-06	0.000287	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CTNNB1—pancreatic cancer	7.64e-06	0.000286	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CNR2—pancreatic cancer	7.64e-06	0.000286	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GLP1R—pancreatic cancer	7.64e-06	0.000286	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—pancreatic cancer	7.64e-06	0.000286	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—pancreatic cancer	7.64e-06	0.000286	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CD—pancreatic cancer	7.62e-06	0.000285	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JAG1—pancreatic cancer	7.6e-06	0.000284	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOTCH3—pancreatic cancer	7.57e-06	0.000283	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ARG2—pancreatic cancer	7.57e-06	0.000283	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCKAR—pancreatic cancer	7.52e-06	0.000281	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—pancreatic cancer	7.49e-06	0.000281	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CNR2—pancreatic cancer	7.48e-06	0.00028	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GLP1R—pancreatic cancer	7.48e-06	0.00028	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—pancreatic cancer	7.47e-06	0.00028	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—pancreatic cancer	7.45e-06	0.000279	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCKAR—pancreatic cancer	7.36e-06	0.000275	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JAG2—pancreatic cancer	7.29e-06	0.000273	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—pancreatic cancer	7.27e-06	0.000272	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MEN1—pancreatic cancer	7.18e-06	0.000269	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CNR1—pancreatic cancer	7.17e-06	0.000268	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JAG2—pancreatic cancer	7.13e-06	0.000267	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CD—pancreatic cancer	7.13e-06	0.000267	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MEN1—pancreatic cancer	7.03e-06	0.000263	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CG—pancreatic cancer	6.95e-06	0.00026	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GCG—pancreatic cancer	6.92e-06	0.000259	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SRC—pancreatic cancer	6.91e-06	0.000259	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SHH—pancreatic cancer	6.85e-06	0.000257	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH4—pancreatic cancer	6.81e-06	0.000255	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IAPP—pancreatic cancer	6.77e-06	0.000253	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.73e-06	0.000252	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—pancreatic cancer	6.73e-06	0.000252	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SHH—pancreatic cancer	6.71e-06	0.000251	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH4—pancreatic cancer	6.66e-06	0.00025	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—pancreatic cancer	6.66e-06	0.000249	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—pancreatic cancer	6.66e-06	0.000249	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRAS—pancreatic cancer	6.65e-06	0.000249	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CB—pancreatic cancer	6.64e-06	0.000249	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IAPP—pancreatic cancer	6.62e-06	0.000248	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMP—pancreatic cancer	6.61e-06	0.000248	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGTR1—pancreatic cancer	6.6e-06	0.000247	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—pancreatic cancer	6.58e-06	0.000246	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STK11—pancreatic cancer	6.51e-06	0.000244	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTHLH—pancreatic cancer	6.5e-06	0.000243	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTCH1—pancreatic cancer	6.5e-06	0.000243	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTHLH—pancreatic cancer	6.36e-06	0.000238	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTCH1—pancreatic cancer	6.36e-06	0.000238	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CB—pancreatic cancer	6.21e-06	0.000233	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—pancreatic cancer	6.19e-06	0.000232	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—pancreatic cancer	6.18e-06	0.000231	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—pancreatic cancer	6.16e-06	0.000231	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CD—pancreatic cancer	6.11e-06	0.000229	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—pancreatic cancer	6.05e-06	0.000227	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SST—pancreatic cancer	5.94e-06	0.000222	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.87e-06	0.00022	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.86e-06	0.000219	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SST—pancreatic cancer	5.82e-06	0.000218	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JAG1—pancreatic cancer	5.81e-06	0.000218	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH3—pancreatic cancer	5.79e-06	0.000217	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—pancreatic cancer	5.74e-06	0.000215	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.74e-06	0.000215	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—pancreatic cancer	5.72e-06	0.000214	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SMAD4—pancreatic cancer	5.7e-06	0.000213	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JAG1—pancreatic cancer	5.69e-06	0.000213	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH3—pancreatic cancer	5.67e-06	0.000212	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—pancreatic cancer	5.64e-06	0.000211	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HES1—pancreatic cancer	5.56e-06	0.000208	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CNR1—pancreatic cancer	5.48e-06	0.000205	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—pancreatic cancer	5.37e-06	0.000201	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CNR1—pancreatic cancer	5.37e-06	0.000201	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GLP1R—pancreatic cancer	5.33e-06	0.0002	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CB—pancreatic cancer	5.33e-06	0.0002	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CG—pancreatic cancer	5.32e-06	0.000199	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GCG—pancreatic cancer	5.3e-06	0.000198	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—pancreatic cancer	5.26e-06	0.000197	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DPYD—pancreatic cancer	5.24e-06	0.000196	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	5.21e-06	0.000195	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GCG—pancreatic cancer	5.18e-06	0.000194	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.15e-06	0.000193	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—pancreatic cancer	5.12e-06	0.000192	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—pancreatic cancer	5.08e-06	0.00019	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGTR1—pancreatic cancer	5.05e-06	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.04e-06	0.000189	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STK11—pancreatic cancer	4.98e-06	0.000186	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	4.98e-06	0.000186	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	4.94e-06	0.000185	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—pancreatic cancer	4.88e-06	0.000183	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STK11—pancreatic cancer	4.87e-06	0.000182	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—pancreatic cancer	4.86e-06	0.000182	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—pancreatic cancer	4.7e-06	0.000176	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CD—pancreatic cancer	4.68e-06	0.000175	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—pancreatic cancer	4.66e-06	0.000175	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSC2—pancreatic cancer	4.65e-06	0.000174	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	4.58e-06	0.000171	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—pancreatic cancer	4.55e-06	0.00017	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.49e-06	0.000168	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KDR—pancreatic cancer	4.46e-06	0.000167	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.39e-06	0.000165	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SMAD4—pancreatic cancer	4.36e-06	0.000163	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—pancreatic cancer	4.32e-06	0.000162	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—pancreatic cancer	4.29e-06	0.000161	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	4.27e-06	0.00016	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HES1—pancreatic cancer	4.26e-06	0.000159	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKBIA—pancreatic cancer	4.24e-06	0.000159	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	4.22e-06	0.000158	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOTCH1—pancreatic cancer	4.2e-06	0.000157	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HES1—pancreatic cancer	4.17e-06	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CG—pancreatic cancer	4.11e-06	0.000154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—pancreatic cancer	4.11e-06	0.000154	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CB—pancreatic cancer	4.08e-06	0.000153	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGF—pancreatic cancer	4.06e-06	0.000152	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—pancreatic cancer	4.05e-06	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.99e-06	0.000149	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—pancreatic cancer	3.92e-06	0.000147	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CD44—pancreatic cancer	3.85e-06	0.000144	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—pancreatic cancer	3.84e-06	0.000144	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	3.84e-06	0.000144	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—pancreatic cancer	3.79e-06	0.000142	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—pancreatic cancer	3.74e-06	0.00014	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—pancreatic cancer	3.73e-06	0.00014	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GCG—pancreatic cancer	3.69e-06	0.000138	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—pancreatic cancer	3.65e-06	0.000137	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CD—pancreatic cancer	3.61e-06	0.000135	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.58e-06	0.000134	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—pancreatic cancer	3.57e-06	0.000134	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSC2—pancreatic cancer	3.56e-06	0.000133	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—pancreatic cancer	3.54e-06	0.000132	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	3.49e-06	0.000131	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	3.48e-06	0.00013	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—pancreatic cancer	3.48e-06	0.00013	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—STK11—pancreatic cancer	3.47e-06	0.00013	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KDR—pancreatic cancer	3.41e-06	0.000128	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—pancreatic cancer	3.41e-06	0.000128	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KDR—pancreatic cancer	3.34e-06	0.000125	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—pancreatic cancer	3.31e-06	0.000124	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—pancreatic cancer	3.25e-06	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	3.25e-06	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	3.21e-06	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	3.18e-06	0.000119	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CB—pancreatic cancer	3.15e-06	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	3.15e-06	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	3.14e-06	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	3.14e-06	0.000118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGF—pancreatic cancer	3.11e-06	0.000116	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—pancreatic cancer	3.09e-06	0.000116	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	3.08e-06	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	3.08e-06	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGF—pancreatic cancer	3.04e-06	0.000114	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—pancreatic cancer	3.03e-06	0.000113	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—pancreatic cancer	3.01e-06	0.000113	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—pancreatic cancer	2.99e-06	0.000112	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—pancreatic cancer	2.92e-06	0.000109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—pancreatic cancer	2.9e-06	0.000108	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	2.86e-06	0.000107	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—pancreatic cancer	2.82e-06	0.000106	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	2.8e-06	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CTNNB1—pancreatic cancer	2.79e-06	0.000104	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	2.76e-06	0.000103	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.74e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—pancreatic cancer	2.74e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—pancreatic cancer	2.72e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	2.71e-06	0.000101	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	2.7e-06	0.000101	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.68e-06	0.0001	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—pancreatic cancer	2.65e-06	9.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	2.65e-06	9.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—pancreatic cancer	2.52e-06	9.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.49e-06	9.31e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	2.46e-06	9.2e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—pancreatic cancer	2.43e-06	9.11e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.43e-06	9.11e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—pancreatic cancer	2.43e-06	9.1e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—pancreatic cancer	2.43e-06	9.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.41e-06	9.02e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	2.36e-06	8.83e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.31e-06	8.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.3e-06	8.61e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	2.27e-06	8.48e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—pancreatic cancer	2.26e-06	8.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	2.26e-06	8.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	2.25e-06	8.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.24e-06	8.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.22e-06	8.29e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—pancreatic cancer	2.21e-06	8.28e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.19e-06	8.21e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	2.19e-06	8.19e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	2.17e-06	8.12e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.16e-06	8.07e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.14e-06	8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.12e-06	7.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	2.11e-06	7.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.09e-06	7.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	2.09e-06	7.83e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—pancreatic cancer	2.09e-06	7.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.08e-06	7.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	2.05e-06	7.67e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	2.04e-06	7.63e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.03e-06	7.6e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	1.99e-06	7.44e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.93e-06	7.23e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.93e-06	7.22e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.92e-06	7.18e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—pancreatic cancer	1.89e-06	7.07e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.88e-06	7.04e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.86e-06	6.97e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.86e-06	6.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.86e-06	6.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.84e-06	6.89e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	1.82e-06	6.82e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	1.82e-06	6.8e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—pancreatic cancer	1.78e-06	6.65e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.73e-06	6.48e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.73e-06	6.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—pancreatic cancer	1.69e-06	6.34e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.69e-06	6.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	1.69e-06	6.32e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.68e-06	6.29e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.67e-06	6.23e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	1.66e-06	6.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.6e-06	5.98e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—pancreatic cancer	1.57e-06	5.87e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	1.56e-06	5.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.47e-06	5.5e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.45e-06	5.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	1.44e-06	5.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.42e-06	5.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—pancreatic cancer	1.39e-06	5.21e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.36e-06	5.09e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	1.33e-06	4.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.2e-06	4.49e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.17e-06	4.4e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.02e-06	3.84e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—pancreatic cancer	8.37e-07	3.13e-05	CbGpPWpGaD
